CCT was most effective in cognitive rehabilitation, particularly in the subdomain of memory. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Extrapolating results to the US population, we estimate that annually nearly a million individuals who are likely eligible for hospice die without its services. 4 key findings →
Design: cohort study Participants: 1,209 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Incident AF was associated with an increased risk of dementia, independent of clinical stroke in an elderly population. 5 key findings →
Design: longitudinal study Participants: 435 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Data from 362 study participants were analyzed (mean [SD] age, 65.6 [7.9] years), of whom 152 (42.0%) were African American, 230 (63.5%) were women, and 189 (52.2%) had MCI. 4 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The positive finding of lower EV Aβ42 supports emerging evidence that plasma neuronal EVs provide an effective platform for demonstrating biomarker responses in clinical trials in AD. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
This study showed that a simple blood test measuring neurofilament light (NfL), a protein released when brain cells are damaged, can detect the earliest signs of brain degeneration in people carrying genes that cause early-onset familial Alzheimer's disease - years before any symptoms appear. 4 key findings →
Design: cohort Participants: 405 Evidence: high
Full summary, score breakdown and related studies → Original source
Early tau deposition was elevated in women compared with men in individuals on the Alzheimer disease trajectory. 5 key findings →
Design: cross-sectional Participants: 89 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
66/100
Statistically significant effects of AZD0530 treatment were not found on relative CMRgl reduction in an Alzheimer disease-associated region of interest or on secondary clinical or biomarker measures. 3 key findings →
Participants: 159 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our analysis extends recent work by revealing specific benefits for instrumental activities of daily living for individuals in the early stages of AD and supports the value of exercise for individuals with cognitive impairment. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Change in occupational performance predicted change in depressive symptoms. 5 key findings →
Design: randomized controlled trial Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A cohort of 4 522 160 US veterans (4 243 462 [93.8%] male; median [interquartile range] age, 64.1 [55.7-75.5] years; 3 702 942 [82.0%] white, 667 550 [14.8%] black, and 145 593 [3.2%] other race) was followed up for a median (interquartile range) of 10.0 (6.8-10.2) years. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Whether the cognitive benefits of physical exercise can improve the overall well-being of this group remains unknown. 2 key findings →
Design: randomized controlled trial Participants: 120 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High levels of caregiver burden are present in a large proportion of caregivers of people with dementia and this increases over time for those without services. 5 key findings →
Design: longitudinal study Participants: 720 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mediation analyses proposed that visceral obesity contributes to deep white matter lesions through increases in proinflammatory cytokines, suggesting a pathomechanistic link. 1 key finding →
Design: longitudinal study Participants: 1,825 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Prospective, population-based studies that recruit participants in mid-life are valuable resources for dementia research. 1 key finding →
Participants: 500,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by a decline in cognitive functions with no validated disease modifying treatment. 1 key finding →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cognitive training is a popular intervention aimed at attenuating age-related cognitive decline, however, the effects of this intervention on brain structure and function have not been thoroughly explored. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Observational epidemiological studies provide valuable information regarding naturally occurring protective factors observed in populations with very low prevalences of vascular disease. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
The purpose of the present study was to explore the effects of computer-based multidomain cognitive training program on Greek patients with Mild Cognitive Impairment (MCI). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our review suggests that MNPIs may improve the global, executive function and memory of PWD in NHs. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
OH and RBD yielded individual and combined negative effects on disability in α-synucleinopathies, reflecting a 'malignant' phenotype of PD with early cognitive impairment and postural instability. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Enrollees in a comprehensive dementia care comanagement program had high engagement in advance care planning, high rates of hospice use, and low acute care utilization near the end of life. 1 key finding →
Design: retrospective cohort Participants: 321 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Even though the provision of PC was empirically recognised as a care step in the management of dementia, there are barriers that hinder access of patients with dementia to appropriate facilities. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
An extensive literature on childhood adversity and neurodevelopment has emerged over the past decade. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →